Akebia Therapeutics, Inc.
AKBA
$0.88
$0.044.15%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 7.52% | 25.69% | 47.46% | 32.49% | 16.75% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.52% | 25.69% | 47.46% | 32.49% | 16.75% |
| Cost of Revenue | 23.24% | 36.73% | 60.00% | 44.15% | 10.45% |
| Gross Profit | 4.49% | 23.50% | 45.13% | 30.39% | 18.05% |
| SG&A Expenses | 6.86% | 4.98% | 0.88% | 4.56% | 5.96% |
| Depreciation & Amortization | -- | -- | -- | -75.00% | -50.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.28% | 9.52% | 2.26% | 0.45% | -4.08% |
| Operating Income | -209.46% | 164.77% | 158.22% | 169.29% | 116.23% |
| Income Before Tax | 23.68% | 58.60% | 94.64% | 66.76% | 9.79% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 18.69% | 54.73% | 92.30% | 65.42% | 9.79% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 18.69% | 54.73% | 92.30% | 65.42% | 9.79% |
| EBIT | -209.46% | 164.77% | 158.22% | 169.29% | 116.23% |
| EBITDA | -117.10% | 9.76% | 461.70% | 491.18% | 376.03% |
| EPS Basic | 35.73% | 64.06% | 94.76% | 65.85% | 14.67% |
| Normalized Basic EPS | 54.47% | 74.58% | 99.79% | 74.24% | 17.80% |
| EPS Diluted | 36.59% | 63.72% | 93.83% | 65.35% | 11.58% |
| Normalized Diluted EPS | 54.60% | 74.61% | 99.47% | 73.77% | 17.37% |
| Average Basic Shares Outstanding | 15.07% | 21.22% | 21.87% | 20.45% | 16.93% |
| Average Diluted Shares Outstanding | 14.30% | 22.44% | 24.74% | 23.33% | 18.69% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |